Breye Therapeutics ApSAktiv

The Company, Breye Therapeutics ApS, is a clinical stage biopharmaceutical company developing first-in-class and orally administered therapies suited for early treatment intervention in patients with diabetic retinopathy (DR) and age-related macular degeneration (AMD) being at risk of further disease progression and vision loss.Diabetic retinopathy is the leading cause of blindness among working age adults and AMD is the leading cause of blindness within the elderly population. Globally there are more than 120 million people suffering from DR and 200 million people have AMD. With more than 1 billion people being obese today and 20% of the world’s population being older than 60 years of age, both eye diseases are projected to increase in prevalence over the coming decades. Currently available therapies require needle injections administered directly into the eye, and despite the burden of repeated needle injections, the market for these therapies has grown to USD 21 billion annually. The prospect of developing orally administered therapies could help very large groups of patients in need of better and non-invasive treatment solutions. The ambition is to treat patients at moderate to severe stages of disease and thereby not only preventing further disease progression to irreversible eye damage, but to halt and reverse the damage already observed.The company's lead therapy, danegaptide, is a clinical asset with a documented safety profile in human trial subjects and has been in

The income statement for 2025/26 shows a loss of DKK 85,575,302 against a loss of DKK 89,139,846 last year, and the balance sheet at 31 March 2026 shows a negative equity of DKK 126,213,092. The loss for the year is associated with the further development of assets and is in line with the expectations of management.Loss of share capitalAs of 31 March 2026, the Company has lost more than 50% of the share capital. Management expects to restablish the share capital through capital increases, debt conversions or a combination hereof.Our Societal Impact and ESG (Environment, Social and Governance) effortBreye is committed to be proactive to help millions of people with better and non-invasive treatment solutions for retinal diseases – and with a global reach by focusing on both access and affordability. We think that a global solution is the combination of AI-guided diagnostic and non-invasive oral treatments. At Breye, our mission and vision are strengthened by our responsibility to work towards sustainable, ethical, and forward-thinking practices. We integrate sustainability into all parts of our value chain. Breye has developed an ESG Policy, which is anchored in on our Shareholders Agreement and with inputs from the Breye Leadership Team. We have an ESG responsible person appointed who works from an approved annual wheel. Our board approves the ESG plans annually and we report to our main investors at least on a yearly basis. To show our commitment, we are a member of UN Globa

Uddrag af ledelsesberetningen i den seneste årsrapport.